Acute congestive heart failure
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1) patient older than 20 years old 2) Patient who is treated acute heart failure presenting clinical scenarios 1 and 2 with carperitide under bladder catheterization 3) patient who is planed to administer tolvaptan because of insufficient diuresis only by intravenous injection frosemide 4) patient with chronic kidney disease (eGFR<60ml/min/1.73m2) 5)patient with depressed left ventricular function (left ventricle ejection fraction <55% or left ventricle shortening rate <26%) 6)patient from whom consent for participation in this clinical study was obtained
Exclusion criteria
Exclusion criteria: 1)patient with acute heart failure presenting clinical scenarios 3, 4, and 5 2)patient to whom tolvaptan has already been administered 3)patient to whom continuous intravenous infusion inotropes (catecholamine, phosphodiesterase-3 inhibitors, colforsin daropate hydrochloride, etc) has already been administered or is planned to be administered 4)patient who has received mechanical support (invasive mechanical ventilation, intraaortic balloon pumping, percutaneous cardiopulmonary support, continuation hemofiltration-dialysis, etc.) or is planned to use it 5)patient who presents shock at enrollment 6)Patient with advanced renal dysfunction (eGFR<30ml/min/1.73m2) 7)patient who is judged to be improper by the doctor in charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| urine volume per 6 hours | — |
Secondary
| Measure | Time frame |
|---|---|
| Relationship between urine AQP2, serume AVP and diuresis effect of tolvaptan | — |
Countries
Japan
Contacts
National Hospital Organization Yokohama Medical Center Department of Cardiology